A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049870/
https://ncbi.nlm.nih.gov/pubmed/21135857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados